Literature DB >> 10417200

Differences in the concentrations of small, anionic, antimicrobial peptides in bronchoalveolar lavage fluid and in respiratory epithelia of patients with and without cystic fibrosis.

K A Brogden1, M R Ackermann, P B McCray, K M Huttner.   

Abstract

Affinity-purified rabbit polyclonal (PAB96-1) and mouse monoclonal (1G9-1C2) antibodies to synthetic H-DDDDDDD-OH, an antimicrobial anionic peptide (AP) originally isolated from ovine pulmonary surfactant, were prepared and used to assess the concentrations of AP-like molecules in human respiratory tract samples. In bronchoalveolar lavage fluids, concentrations of AP-like molecules measured by enzyme-linked immunosorbent assay were significantly lower in 13 patients with cystic fibrosis (CF) (mean +/- standard deviation [SD], 0.78 +/- 0.46 mM) than in 34 patients without CF (1. 30 +/- 0.66 mM) (P = 0.01). In pulmonary tissues of three patients without CF, very little antigen was stained in the apical cytoplasm of the bronchial and bronchiolar epithelium yet robust staining was seen in the alveolar epithelium. In pulmonary tissues of three patients with CF, robust staining of antigen was seen in the apical cytoplasm of the bronchial and bronchiolar epithelium yet no staining was seen in the alveolar epithelium. These results show that AP-like molecules are present in healthy human respiratory tract samples and differ in concentration and location of expression in patients with and without CF.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417200      PMCID: PMC96733     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis.

Authors:  M J Goldman; G M Anderson; E D Stolzenberg; U P Kari; M Zasloff; J M Wilson
Journal:  Cell       Date:  1997-02-21       Impact factor: 41.582

Review 2.  Cystic fibrosis.

Authors:  P B Davis; M Drumm; M W Konstan
Journal:  Am J Respir Crit Care Med       Date:  1996-11       Impact factor: 21.405

3.  Antibacterial activity of antileukoprotease.

Authors:  P S Hiemstra; R J Maassen; J Stolk; R Heinzel-Wieland; G J Steffens; J H Dijkman
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

4.  Sublethal damage of Escherichia coli by lung lavage.

Authors:  F M Laforce; D S Boose
Journal:  Am Rev Respir Dis       Date:  1981-12

5.  Human airway epithelia express a beta-defensin.

Authors:  P B McCray; L Bentley
Journal:  Am J Respir Cell Mol Biol       Date:  1997-03       Impact factor: 6.914

6.  Detection of anionic antimicrobial peptides in ovine bronchoalveolar lavage fluid and respiratory epithelium.

Authors:  K A Brogden; M Ackermann; K M Huttner
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

7.  Antimicrobial peptides of lactoferrin.

Authors:  M Tomita; M Takase; H Wakabayashi; W Bellamy
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

8.  Isolation of an ovine pulmonary surfactant-associated anionic peptide bactericidal for Pasteurella haemolytica.

Authors:  K A Brogden; A J De Lucca; J Bland; S Elliott
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

9.  Isolation of an antibacterial peptide from human lung lavage fluid.

Authors:  R T Ellison; D Boose; F M LaForce
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

10.  Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.

Authors:  J J Smith; S M Travis; E P Greenberg; M J Welsh
Journal:  Cell       Date:  1996-04-19       Impact factor: 41.582

View more
  8 in total

1.  Increased anionic peptide distribution and intensity during progression and resolution of bacterial pneumonia.

Authors:  Amanda J Fales-Williams; Jack M Gallup; Rafael Ramírez-Romero; Kim A Brogden; Mark R Ackermann
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

Review 2.  Antimicrobial peptides: current status and therapeutic potential.

Authors:  Andreas R Koczulla; Robert Bals
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Collectins and cationic antimicrobial peptides of the respiratory epithelia.

Authors:  B Grubor; D K Meyerholz; M R Ackermann
Journal:  Vet Pathol       Date:  2006-09       Impact factor: 2.221

Review 4.  Antimicrobial peptides and surfactant proteins in ruminant respiratory tract disease.

Authors:  David K Meyerholz; Mark R Ackermann
Journal:  Vet Immunol Immunopathol       Date:  2005-10-18       Impact factor: 2.046

Review 5.  The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Authors:  D Banerjee; D Stableforth
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

Review 6.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

Review 7.  Epithelial antimicrobial peptides in host defense against infection.

Authors:  R Bals
Journal:  Respir Res       Date:  2000-10-20

8.  Zn-Enhanced Asp-Rich Antimicrobial Peptides: N-Terminal Coordination by Zn(II) and Cu(II), Which Distinguishes Cu(II) Binding to Different Peptides.

Authors:  Adriana Miller; Agnieszka Matera-Witkiewicz; Aleksandra Mikołajczyk; Joanna Wątły; Dean Wilcox; Danuta Witkowska; Magdalena Rowińska-Żyrek
Journal:  Int J Mol Sci       Date:  2021-06-28       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.